CD123+expression was found in 50% of the studied B-ALL patients (33.3% in the double-positive CD25+/CD123+ group plus 16.7% in the single-positive CD25−/CD123+ group). This evidence concerns the gene IL2RA and precursor B-cell acute lymphoblastic leukemia.